Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 11/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 6/20 | 0.40 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25238651 | 1.00 | BTK (0.46) | BTKLCKNAMPTDGAT2CYP11B2 | |
| SCHEMBL29418739 | 1.00 | BTK (0.46) | BTKLCKNAMPTDGAT2CYP11B2 | |
| SCHEMBL29418303 | 0.95 | BTK (0.48) | BTKLCKNAMPTDGAT2 | |
| SCHEMBL25223228 | 0.95 | BTK (0.48) | BTKLCKNAMPTDGAT2 | |
| SCHEMBL25267538 | 0.92 | BTK (0.48) | BTKLCKDGAT2 | |
| SCHEMBL25214221 | 0.90 | BTK (0.48) | BTKLCKNAMPTDGAT2 | |
| SCHEMBL29418480 | 0.90 | BTK (0.48) | BTKLCKNAMPTDGAT2 | |
| SCHEMBL25252826 | 0.89 | BTK (0.46) | BTKLCKDGAT2 | |
| SCHEMBL29418551 | 0.89 | BTK (0.46) | BTKLCKDGAT2 | |
| SCHEMBL25215358 | 0.88 | BTK (0.50) | BTKLCKDGAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327380-A1 | BTK INHIBITORS | BIOGEN MA INC. (US) | 2024-10-03 | — | — | US | disclosed |
| CN-116917279-A | BTK inhibitors | 渤健马萨诸塞州股份有限公司 | 2023-10-20 | — | — | CN | disclosed |
| EP-4192587-A1 | BTK INHIBITORS | Biogen MA Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| WO-2022032019-A1 | BTK INHIBITORS | BIOGEN MA INC. (US) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327380-A1 | BTK INHIBITORS | BTK, SYK, LYN | BTK 1/4885LCK 7/4885NAMPT 2439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.